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ABSTRACT  
Objectives: Surveillance is a key component of any control strategy for health-care associated 
infections (HAIs) and antimicrobial resistance (AMR), and public availability of 
methodological aspects is crucial for the interpretation of the data. We sought to 
systematically review publicly available information for HAIs and/or AMR surveillance 
systems organised by public institutions or scientific societies in European countries. 
Methods: A systematic review of scientific and grey literature following the Preferred 
Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines was 
performed. Information on HAIs and/or AMR surveillance systems published until October 
31, 2016 were included. 
Results: 112 surveillance systems were detected; 56 from 20 countries were finally included. 
Most exclusions were due to lack of publicly available information. Regarding antimicrobial 
resistance, the most frequent indicator was the proportion of resistant isolates (27 of 34 
providing information, 79.42%); only 18 (52.9%) included incidence rates; the data were only 
laboratory-based in 33 of the 42 providing this information (78.5%). Regarding HAIs in 
intensive care units, all 22 (100%) the systems providing data included central line-associated 
bloodstream infections, and 19 (86.3%) ventilator-associated pneumonia and catheter-
associated urinary tract infections; incidence density was the most frequent indicator. 
Regarding surgical site infections, the most frequent procedures included were hip prosthesis, 
colon surgery and caesarean section (21 out of 22, 95.5% of the systems). 
Conclusions: Publicly available information about the methods and indicators of the 
surveillance system is frequently lacking; despite the efforts of ECDC and other organisations, 
there is still a wide heterogeneity in procedures and indicators.  
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Registration: The SUSPIRE protocol was registered in the International Prospective Register 
of Systematic Reviews (PROSPERO) on 12 February 2016. Protocol registration number: 
CRD42016033867. 
 
Keywords: Antimicrobial resistance; healthcare-associated infections; surveillance; 
epidemiology; systematic review 
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INTRODUCTION 
 
Health-care associated infections (HAIs) are well recognised causes of avoidable 
morbidity, mortality, and costs of care [1]. Additionally, the emergence and spread of 
antimicrobial resistance (AMR) is now considered a global public health threat [2, 3]. Both 
problems, HAIs and AMR are intrinsically related and may act synergistically within 
hospitals. Surveillance of HAIs and AMR are key parts of any control strategy [4]. 
Surveillance data have been traditionally used to detect problems, prioritise resources, 
evaluate control programmes and provide feedback. Appropriate descriptions of the 
methodology used and assessment of quality of data are critical to adequately interpret the 
information provided by surveillance; however, to our knowledge, the public availability of 
methodological information of the surveillance systems and their appropriateness has not been 
systemically reviewed. Additionally, during the last decades, surveillance data are been 
increasingly used and demanded for benchmarking and public reporting [5], which is 
controversial due to heterogeneity in methodology, inadequate control of confounders and 
different quality of data. Significant methodological heterogeneity in surveillance activities 
was shown by the European Centre for Disease Control and Prevention (ECDC) in 2008 [6]. 
In 2009, the European Council recommended to establish or strengthen active surveillance 
systems at national or regional level [7]; ECDC is leading a huge effort through the 
establishment of HAI-Net, a network of national/regional networks collecting surveillance 
data across Europe. Despite these efforts, heterogeneity in national surveillance methods and 
activities might still be important among European countries.  
An additional potential result of surveillance activities might be to inform the burden 
of specific syndromes caused by resistant pathogens (e.g., the incidence rate of pneumonia 
caused by carbapenemase-producing Enterobacteriaceae) in order to better identify priorities 
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for research. Additionally, the identification of the patients’ features would contribute to more 
efficient recruitment in randomised controlled trials by choosing sites with higher rates and 
patient population at higher risk of the target infections. To our knowledge, whether present 
surveillance systems provide useful information for these purposes has not been analysed.  
The objectives of this work were: (a) to catalogue, review and summarise the 
information publicly available from active, official surveillance systems in European countries 
or regions; (b) to identify the main differences in methodological aspects and indicators used; 
and (c) to analyse the potential gaps to inform next steps in harmonisation processes. This 
study was performed under the auspices of EPI-Net, an epidemiological network for 
antimicrobial resistance and healthcare-associated infections formed as an outcome of the 
COMBACTE-MAGNET project, funded by the Innovative Medicines Initiative (IMI). 
 
METHODS 
 
A systematic scientific and grey literature search and review of surveillance systems 
for HAIs and/or AMR developed or endorsed by official institutions in Europe was 
performed. The study protocol and methodology, which followed the Preferred Reporting 
Items for Systematic Reviews and Meta-analyses (PRISMA) guideline [8], was previously 
published [9].  
 
Information Sources and searching strategies 
Two independent strategies were followed. First, peer-reviewed literature (PubMed, 
EMBASE and Scopus) was systematically searched. References from the retrieved articles 
were also reviewed for potential additional articles. No language restrictions were applied. An 
example for the search strategy designed for the peer-reviewed literature for AMR is 
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"Antimicrobial resistan*" OR "Antibiotic resistan*" OR "Multidrug resistan*" AND 
Surveillance NOT reviews AND ("last 10 years"[PDat]); ((Surveillance [MeSH Terms]) AND 
Spain [MeSH Terms]) AND "Antimicrobial resistan*"; "epidemiology"[Mesh] AND 
"antimicrobial resistance" NOT animals. 
Second, a comprehensive grey literature search included Google search engine and 
websites from the ministries of health, healthcare services, institutes of public health, 
European Centre for Disease Prevention and Control (ECDC), World Health Organization 
(WHO), scientific societies in the field (including the European Society of Clinical 
Microbiology and Infectious Diseases [ESCMID], the International Society for Infectious 
Diseases [ISID]; the International Epidemiological Association [IEA], the European Society 
of Intensive Care Medicine [ESICM] and the European Respiratory Society [ERS]). The 
search strategy used the following terms in English and local languages: "Antimicrobial 
resistance" AND/OR "Hospital-associated" OR "Hospital-acquired" OR "Nosocomial" AND 
"Surveillance" AND "epidemiology" OR "prevalence" OR "incidence". The time period was 
until October 31, 2016. Also, after the data were reviewed, the national representatives of the 
European Committee on Infection Control (EUCIC) of ESCMID were consulted as additional 
source to detect specific publicly available documents that might have been missed with our 
search strategy and for helping with the translation of specific terms. Anyway, only data from 
publicly available information was included in the review. 
 
Eligibility criteria 
We selected the information related to the 32 European countries, including the 28 
European Union member states and the four countries from the European Free Trade 
Association (EFTA) (Iceland, Liechtenstein, Norway and Switzerland). 
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A HAIs or AMR surveillance system was defined as a structured and systematic 
procedure to measure the prevalence or incidence cases of HAIs and/or AMR, performed 
continuously or periodically, with a defined methodology and specified indicators. The 
inclusion criteria were: data were reported for at least one year period since 2006; the 
methodology was publicly available for review; and the system was promoted or endorsed by 
a regional, national or transnational official health organisations or scientific society. 
Surveillance systems referring their methodology to transnational systems (like those 
promoted by ECDC) were included. 
Exclusion criteria were: systems exclusively declaring/notifying individual cases of a 
specific disease or pathogen (e.g., compulsory reporting of individual cases) not to be reported 
as proportion of cases, or cases per person or person-days at risk (rates); systems providing 
only animal, environmental or food data; surveillance data promoted by private companies; 
and outbreaks reports. Regional systems using the same methodology as national systems 
were also excluded.  
Three independent reviewers (MNN, MDN and NBR) performed a two-step selection 
process. Titles and abstracts of the retrieved documents were initially assessed and non-
relevant documents excluded. For data from grey literature, executive summaries, table of 
contents and documents (whichever was available) were screened. The full text of potentially 
eligible documents were then obtained and assessed for relevance or duplication against 
predefined selection criteria. When available, national experts were contacted to clarify 
protocol details. 
 
Data extraction and analysis 
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Data extraction was limited to publicly available information, and was performed by 
the same authors. Disagreements were resolved by review and consensus with other co-
authors (JRB and ET).  
The data collected included the scope, population covered, quality assessment, dates of 
the information available; for AMR systems, pathogens, antimicrobials, definitions, inclusion 
criteria, risk factors, and indicators; for HAI surveillance systems in intensive care units 
(ICUs), risk factors, indicators for device related-infections (central line-associated 
bloodstream infections [CLABSI], ventilator-associated pneumonia [VAP] and catheter-
associated urinary tract infection [CAUTI]); and outcome data; and for surgical site infections, 
inclusion of urgent interventions, antibiotic prophylaxis, procedure indicators, and the 
interventions included. Variables for which information was not specified or was not available 
were computed as “not reported/unknown”. 
We did not seek ethical approval for this study because data collected is not linked to 
individuals. The data are shown in a descriptive manner and stratified whenever possible by 
country/region, scope, population, settings, and major outcome (HAI and/or AMR control).     
 
RESULTS 
 
We detected 112 surveillance programmes/activities from 27 countries/regions. After 
reviewing the available data, 56 surveillance programmes were included (online 
supplementary Table S1). Noteworthily, information was not publicly available for the 
surveillance systems in 12 (21.4%) countries (Bulgaria, Cyprus, Czech Republic, Estonia, 
Iceland, Latvia, Liechtenstein, Luxembourg, Malta, Poland, Romania and Slovenia).  
Of the 56 surveillance systems included, 33 (58.9%) target HAIs and 45 (80.3%) target 
AMR; 22 target both. The general features of the systems are shown in the online 
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supplementary Table S2. In summary, the coverage of the systems was national in 35, regional 
in 17 and transnational in 4. Among the national systems, 8 (22.5%) were focused on HAI 
only, 16 (45.7%) in AMR only, and 11 (31.4%) in both; external quality audits were applied 
or recommended in 13 systems (37.1%), and some type of internal quality assessment was 
reported in 5 (14.2%). 
 
Surveillance systems for AMR  
Data were available for 42 systems from 20 countries, and for the 4 transnational 
systems. The features of the 46 national, regional and transnational system are specified in 
online supplementary Table S3; the aggregated data for the 42 regional and national systems 
are summarised in Table 1. Among the latter, information about the susceptibility 
interpretative criteria used was available for 26 systems (61.9%); among these, the European 
Committee for Antimicrobial Susceptibility Testing (EUCAST) breakpoints were used in 22 
(84.6%); in 9 of them, Clinical Laboratory Standards Institute (CLSI) breakpoints were used 
for some pathogens; in 3 (11.5%) and 1 (3.8%), local and CLSI criteria were the only used, 
respectively.  
Data on the indicators used were available in 34 systems (80.9%). Among them, the 
most frequent indicator was the percentage of resistant isolates to specific drugs (27 systems, 
79.4%; 64.2% of all systems); this was the only indicator in 16 (47.0%; 38.0% of all systems); 
18 (52.9%; 42.8% of all systems) included indicators based on incidence (either as cumulative 
incidence or incidence density) as indicators. It is also important to notice that outcome data 
were not included in any system. 
Regarding the pathogens, most of the systems included data on Streptococcus 
pneumoniae, Staphylococcus aureus, Enterococcus spp., Escherichia coli, Klebsiella 
pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii; online supplementary 
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Tables S4 and S5 show the antibiotics considered per pathogen in each system, and the 
aggregated data are summarised in Table 2. As regards specific mechanisms of resistance, 11 
(55%) countries had at least one surveillance system reporting actively data on extended 
spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and 9 (45%) on carbapenemase-
producing Enterobacteriaceae. Clostridium difficile was also included in most of them. 
Overall, there was a marked heterogeneity regarding the types of microbiological samples 
considered (online supplementary Tables S4 and S5). 
 
Surveillance of HAI in intensive care units (ICUs) 
A description of key features and indicators used in each surveillance systems of HAIs 
in ICU patients is showed in online supplementary Table S6. Overall, 32 systems plus one 
transnational system were included. Information about indicators was provided in 22 systems 
(68.6%). The most frequent indicators specified for device related-infections were density of 
incidence (all 22 providing information about indicators [100%] for CLABSI, and 19 [86.3%] 
for VAP and CUTI); 14 systems (63.6%) also included the device utilization rates. When all 
systems were considered, individual predisposing factors were collected in 20 systems overall 
(62.5%); as outcome measures, 16 (48.5%) included mortality during ICU stay, and 4 (12.1%) 
also included the length of ICU stay.  
 
Surveillance of surgical site infections (SSI)  
The features of the 32 systems for SSI plus the transnational ECDC programme are 
also shown in online supplementary Table S6. Data about stratification according to risk were 
provided by 19 systems (57.6%) and included the NNIS risk index in all of them; urgent 
procedures were included in 17 (51.5%) and data on antibiotic prophylaxis were collected in 
16 (48.5%). For the 22 surveillance systems providing the type of interventions, the most 
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commonly included were: hip prosthesis, colon surgery and caesarean section in 21 systems 
(95.5%); cholecystectomy in 20 (90.9%); knee prosthesis in 19 (86.4%); coronary artery by-
pass grafting in 18 (81.8%); cardiac valve replacement in 13 (59.1%); and laminectomy in 9 
(40.9%). Data on procedure indicators such as checklist were included only in 17 systems 
overall (51.5%). 
 
DISCUSSION 
 
The most important findings in this systematic review of surveillance systems for 
HAIs and AMR in Europe are: (a) publicly available information on important methodological 
aspects and indicators measured are frequently lacking; (b) methodological heterogeneity 
across countries/regions was found in many aspects; and (c) in the case of AMR, there is a 
low frequency of systems including indicators based on incidence and clinical information.  
 Nevertheless, the data reported suggest important improvements in the homogeneity of 
surveillance activities with regard to previous reports [6] probably as a consequence of ECDC 
activities. First, the number of countries/regions with comprehensive systems has increased; in 
2008, only 16 of 32 countries (50%) had surveillance programmes for surgical site infections 
and 10 (31.2%) for ICU-acquired infections. And second, for ICU infections and SSI the 
indicators are reasonably homogeneous. However, there are still important differences in the 
surgical procedures included in each country/region, which might be primarily be related to 
specific objectives, requirements in a given geographical area and in many occasions, in the 
available resources in each hospital 
Of note, the inclusion of most procedures is voluntary in many systems. Additionally, 
surveillance of adherence to process indicators is still lacking in most surveillance protocols. 
Implementation of successful prevention bundles including assessment of the adherence to the 
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measures included in the bundle has been associated with reduced rates of CLABSI and SSI 
[10, 11], but some studies have found contradictory results [12]. Such activities have a strong 
rationale but require more resources. Homogeneous inclusion of such indicators in national or 
regional systems would benefit from guidance and consensus on the specific indicators, 
definitions and monitoring system. We did not collect information about other types of HAIs 
such as CLABSI, CUTI or healthcare-associated pneumonia outside ICUs. Information about 
these infections are being collected within the HAI-Net module for point prevalence surveys 
performed yearly [13].  
There seem to be more heterogeneity in surveillance activities for AMR. In 2000, 
Monnet reviewed the international AMR surveillance initiatives in Europe [14], and detected 
four supported by public funding (WHO/AR, EARSS, INSPEAR and ESAR) and two with 
corporate funding (TSN and SENTRY). As in 2016, all countries participated in EARS-Net 
(the continuation of EARSS) and some also in the WHO initiatives (GLASS and CAESAR). 
However, only a few collect incidence-based indicators and even fewer collect data on 
specific infections and risk factors. The information provided by EARS-Net is of upmost 
importance from many perspectives, but it should be noted that it is a population-based 
system, do not provide incidence rates, and do not differentiate between nosocomial and 
community-onset episodes; in fact, wrong interpretations of these data may be misleading, as 
some authors recently suggested when analysing the conclusions obtained with extrapolation 
of the EARS-Net data (among other sources of information) to predict the expected burden of 
disease cause by resistant bacteria during future years [15]. Also, information about the type 
of infections caused by the resistant bacteria, outcomes and specific risk factors are usually 
lacking. As a consequence, the information about the real burden of specific infections caused 
by AMR pathogens or their health impact is very limited. The increasing availability of 
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automated information may improve this in the near future [16], but again guidance is needed 
to help decide the data to collect and the operational definitions.  
The use of surveillance data for benchmarking is unavoidable despite all the present 
limitations of the systems. Therefore, the centres may be reluctant to provide real data to 
national or regional systems, but quality assessment of the data is mostly lacking. One of the 
biggest problems of many systems is the fact that reporting of results are performed yearly, 
which makes them useless in terms of real time action. Therefore, such surveillance systems 
would need to be able to provide data within an appropriate time frame, or ideally, in real 
time. 
We were surprised to see the difficulties for accessing to the protocols of HAIs and 
AMR surveillance activities in many countries. For some countries the protocols could not be 
found and in many others, the protocols were not detailed enough. Therefore the fact that for 
many data we could not obtain information is one of the limitations of this review; while the 
available information strongly suggest that more homogeneity is needed, we acknowledge that 
part of the observed heterogeneity in the methodology of surveillance might actually be more 
related to an inadequate public reporting of detailed information. Nevertheless, this also 
reflects a lack of transparency in the procedures recommended and performed in many areas. 
The fact that surveillance data are not frequently made public further challenge the collection 
of informative data. 
Finally, the information provided by the surveillance systems with the reported 
methodologies does not seem to be useful for the design of future randomised trials with older 
or newer drugs. If there is a drug potentially useful against several pathogens, which are 
causing different types of infections, it would be useful to know which of those infections are 
more frequent, in which populations they predominantly occur, and which are their clinical 
implications in order to decide the priority target for a trial and in which regions or countries 
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and patient population should the trial be performed. We do think that surveillance may 
provide useful information in this regard, so that research investment are efficiently aiming to 
the real problems. Of course, such efforts require more resources, and therefore the feasibility 
and sustainability is to be considered. This is one of the areas in which EPI-Net is working 
and will try to help and built a complementary surveillance structure to fill this need.  
This study has limitations that should be considered when interpreting the data. First, 
despite the fact that we used different sources of information, we may have been unable to 
find or adequately interpret relevant publicly available information about some surveillance 
systems. Second, we already stated the problem regarding the fact that the available 
information was sometimes not detailed enough which may not reflect problems in the 
methodology but in reporting. Finally, the structured format used to collect the data might not 
have been able to perfectly capture the information provided in some systems.     
In summary, while some harmonisation has been reach, there is still much room for 
improvement in surveillance systems in European countries regarding the quality of 
surveillance and homogeneity of indicators and procedures. 
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Table 1.  Features of 42 national and regional surveillance systems on antimicrobial resistance 
included in the review. 
 
Variable  Systems (percentage) 
Source of data Laboratory only 33 (78.5) 
Laboratory and patients’ charts 8 (19.0) 
Unknown/not reported 1 (2.3) 
Duplicates policy Duplicates excluded 25 (59.5) 
Case definition Isolates from clinical samples 22 (52.3) 
Infections  10 (23.8) 
Unknown/not reported 10 (23.8) 
Indicators Proportion of resistant isolates* 27 (64.2) 
Cumulative incidence* 11 (26.1) 
Incidence density* 12 (28.5) 
Unknown/not reported 8 (19.0) 
Pathogens specified Streptococcus pneumoniae 32 (76.1) 
Staphylococcus aureus 41 (97.6) 
Enterococcus spp. 31 (73.8) 
Escherichia coli 38 (90.4) 
Klebsiella pneumoniae 36 (85.7) 
Pseudomonas aeruginosa 34 (80.9) 
Acinetobacter baumannii 35 (83.3) 
Clostridium difficile 22 (52.3) 
 
*Not mutually exclusive 
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Table 2. Drugs or drug families included in the 42 national and regional antimicrobial 
resistance surveillance systems    
 
Pathogen Antimicrobial agent/s Systems (percentage) 
Streptococcus pneumoniae Penicillin 24 (58.1) 
Cefotaxime/ceftriaxone 19 (45.2) 
Fluroquinolones 19 (45.2) 
Macrolides 21 (50.0) 
Staphylococcus aureus Oxacillin 34 (80.9) 
Fluroquinolones 19 (45.2) 
Vancomycin 22 (52.3) 
Linezolid 18 (42.8) 
Aminoglycosides 15 (35.7) 
Enterotococcus spp. Ampicillin 26 (61.9) 
Vancomycin 30 (71.4) 
Aminoglcosides* 18 (42.8) 
Escherichia coli / 
Klebsiella pneumoniae 
Amoxicillin-clavulanate 24 (57.1) 
3rd gen. cephalosporins 29 (69.0) 
Carbapenems 28 (66.6) 
Fluoroquinolones 24 (57.1) 
Aminoglycosides 21 (50.0) 
Pseudomonas aeruginosa Ceftazidime/cefepime 28 (66.6) 
Carbapenems 28 (66.6) 
Piperacillin-tazobactam 26 (61.9) 
Fluoroquinolones 25 (59.5) 
Aminoglycosides 23 (54.7) 
Acinetobacter baumannii Carbapenems 26 (61.9) 
Colistin 26 (61.9) 
Tigecycline 14 (33.3) 
Sulbactam 14 (33.3) 
 
